- |||||||||| sodium valproate / Generic mfg., levetiracetam / Generic mfg., brivaracetam / Generic mfg.
Journal: Predictors of clinically significant anhedonia in refractory epilepsy. (Pubmed Central) - Jan 15, 2024 High seizure burden in medication refractory epilepsy is significantly associated with anhedonia. Specific antiseizure medications are also associated with the development of anhedonia, but it is unclear whether their use is causative or influenced by the presence of anhedonia.
- |||||||||| Review, Journal: Status epilepticus in the ICU. (Pubmed Central) - Dec 20, 2023
Initial management consists of rapid administration of benzodiazepines and one of the following non-sedating intravenous antiseizure medications (ASM): (fos-)phenytoin, levetiracetam, or valproate; other ASM are increasingly used, such as lacosamide or brivaracetam...At this step, management may include non-sedating or sedating compounds including ketamine and barbiturates...Short-term mortality ranges from 10 to 15% after SE and is primarily related to increasing age, underlying etiology, and medical comorbidities. Refractoriness of treatment is clearly related to outcome with mortality rising from 10% in responsive cases, to 25% in refractory, and nearly 40% in super-refractory SE.
- |||||||||| brivaracetam / Generic mfg.
Trial completion, Enrollment change: Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study (clinicaltrials.gov) - Dec 19, 2023 P=N/A, N=51, Completed, Refractoriness of treatment is clearly related to outcome with mortality rising from 10% in responsive cases, to 25% in refractory, and nearly 40% in super-refractory SE. Active, not recruiting --> Completed | N=200 --> 51
- |||||||||| brivaracetam / Generic mfg.
Journal: Electrotherapeutical stellate ganglion block on a (Pubmed Central) - Nov 27, 2023 Longitudinal evaluation with repeated application of the E AEP along with changes of drug treatment is in progress. Anticonvulsant therapy was difficult in this case due to persisting epilepsy with already dual therapy (lamotrigine and brivaracetam) at high dosage...A
- |||||||||| brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury (clinicaltrials.gov) - Nov 21, 2023 P1/2, N=24, Active, not recruiting, Anticonvulsant therapy was difficult in this case due to persisting epilepsy with already dual therapy (lamotrigine and brivaracetam) at high dosage...A Trial completion date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
- |||||||||| brivaracetam / Generic mfg.
Anti-epileptogenic effects of early administration of brivaracetam in rats after severe traumatic brain injury (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_11688; BRV treatment reduced injury-induced seizure susceptibility by 50%, bringing the proportion of CCI rats that exhibited seizures down to sham-control levels. These results demonstrate the utility of the 4-AP challenge as a test for epileptogenesis in this TBI model and suggest that early, post-injury administration of BRV may prevent the posttraumatic epileptogenic process.
- |||||||||| brivaracetam / Generic mfg.
Evaluation of Brivaracetam Alone or as an Adjunct Therapy Against Cholinergic-Induced Status Epilepticus in Rats (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_5824; Although the combination therapies with brivaracetam were not as effective on reduction of seizure severity and brain damage as our previously published reports on combinations that included phenobarbital or valproate, the current study reports potential for brivaracetam to improve outcome compared to midazolam monotherapy. Further research is needed to identify the most optimal drug combinations against cholinergic-induced SE.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Review, Journal: Management of epilepsy during pregnancy and lactation. (Pubmed Central) - Sep 13, 2023 Insufficient data exist to reach strong conclusions about the newest antiseizure medications such as eslicarbazepine, perampanel, brivaracetam, cannabidiol, and cenobamate...In general, breastfeeding does not appear to add any additional long term risks to the child. Creative ways of optimizing registry enrollment and data collection are needed to enhance patient safety.
- |||||||||| Diacomit (stiripentol) / Biocodex, Meiji Seika
Biomarker, Journal: A real-life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy. (Pubmed Central) - Sep 7, 2023 ABCB1 polymorphisms related to drug-resistance (3435 CC) or drug-sensitive phenotype (CT or TT) were found in 6 out of 7 patients. Pharmacogenomic testing on saliva proved easy and safe in clinical practice to convey information for the management of epileptic patients, especially those resistant to treatment or sensitive to severe ADRs.
- |||||||||| brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures (clinicaltrials.gov) - Jul 31, 2023 P3, N=70, Active, not recruiting, The results should be interpreted with caution given the retrospective nature of the study and the quantities of missing data at later time points. Trial completion date: Jul 2025 --> Jul 2029 | Trial primary completion date: Jul 2025 --> Jul 2029
- |||||||||| brivaracetam / Generic mfg.
Journal: Synthesis of the Brivaracetam Employing Asymmetric Photocatalysis and Continuous Flow Conditions. (Pubmed Central) - Jul 3, 2023 Continuous flow conditions were employed to improve the efficiency and allow an easy scale-up of the enantioselective photochemical reaction step. The intermediate obtained from the photochemical step was converted into BRV by two different pathways, followed by one alkylation and amidation, thus giving the desired active pharmaceutical ingredients (API) in 44% overall yield, 9:1 diastereoisomeric ratio (dr) and >99:1 enantiomeric ratio (er).
- |||||||||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Journal: Synergistic effects of vagus nerve stimulation and antiseizure medication. (Pubmed Central) - Jun 27, 2023 Our data suggest that the combination of VNS with ASMs belonging to either SV2A modulators or slow sodium channel inhibitors could be optimal to achieve a better seizure control following VNS. However, these preliminary data require further validation under controlled conditions.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Review, Journal: Antiseizure Medication-Induced Alopecia: A Literature Review. (Pubmed Central) - Jun 27, 2023 Alopecia should be considered one important adverse effect of ASMs. Patients reporting hair loss with ASM therapy should be further investigated, and specialist consultation is recommended.
- |||||||||| brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas (clinicaltrials.gov) - Jun 6, 2023 P1, N=30, Recruiting, Because CDs frequently pharmacokinetically interact with ASMs, the cumulative AE profile must be considered. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury (clinicaltrials.gov) - May 12, 2023 P1/2, N=24, Active, not recruiting, The results of this case control study of FDA adverse event reports spanning 10 Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
- |||||||||| Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy. (Pubmed Central) - Apr 14, 2023 Cenobamate improved QALYs and was less costly than brivaracetam, eslicarbazepine, lacosamide, and perampanel. Therefore, cenobamate may be considered as a cost-effective adjunctive antiseizure medication for people with drug-resistant focal seizures.
- |||||||||| New Onset Refractory Status Epilepticus Shaking Up the Intensive Care Unit (Walter E. Washington Convention Center, Area C, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_5039;
The patient was intubated and treated with Propofol, Dexmedetomidine, Fosphenytoin, and Levetiracetam. Due to persistent generalized seizures, she was transferred to a tertiary hospital, where Brivaracetam, Cenobamate, Lacosamide, Levocarnitine, Perampanel, and Zonisamide, and Ketamine and Pentobarbital drips were tried, but did not fully control the patient
|